Statement from JDRF Vice President of Research, Sanjoy Dutta, Ph.D., on the appointment of Kevan Herold, M.D., to TrialNet Chair
“JDRF congratulates Dr. Kevan Herold on his appointment as the new TrialNet Chair. Dr. Herold has been a trusted JDRF collaborator and partner since 1988 when he first received JDRF funding. Over the past 33 years, Dr. Herold has worked tirelessly to advance our understanding of T1D, working alongside JDRF to develop disease-modifying therapies that change the disease’s course. TrialNet is a clinical trial network critical to JDRF’s research strategy, which tests potential therapies to prevent T1D.
Dr. Herold’s innovation is the immune-modulating drug, teplizumab, including four clinical trials in new-onset T1D and the landmark Teplizumab TrialNet Clinical Study. This study was conducted by TrialNet at the direction of Dr. Herold and Carla Greenbaum, M.D., and the first to demonstrate a delay in the onset of T1D in at-risk children and adults. This trial was an enormous step forward in the development of therapies to treat T1D. Without his work, this drug would not currently be under review at FDA. This study was funded in part by JDRF and the National Institutes of Health via the Special Diabetes Program.
JDRF would also like to thank Carla Greenbaum, M.D., for her years of service to the T1D community as the recent TrialNet Chair. Under her leadership, TrialNet conducted key research, including the groundbreaking Teplizumab Prevention Study. We look forward to continuing to work with her in her roles as Director of the TrialNet Hub and Clinical Center Director for the Benaroya Research Institute.”
– JDRF Vice President of Research, Sanjoy Dutta, Ph.D.